Skip to content

To compare the effect of bupivacaine liposome injection and ropivacaine hydrochloride injection on the quality of recovery after laparoscopic cholecystectomy

To compare the effect of bupivacaine liposome injection and ropivacaine hydrochloride injection on the quality of recovery after laparoscopic cholecystectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090767
Enrollment
Unknown
Registered
2024-10-12
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallstones, Cholecystitis, Gallbladder polyps, Cholelithiasis

Interventions

Bupivacaine liposome injection group (Group BL):Bupivacaine liposome injection locally infiltrated the anesthetic wound
Ropivacaine hydrochloride injection group (Group RP):Ropivacaine hydrochloride injection 15ml local infiltration anesthesia wound

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-65 years old, regardless of gender; (2) BMI of 18 ~ 30kg/m2; (3) ASA grade I and II; (4) Patients who plan to undergo laparoscopic cholecystectomy under general anesthesia; (5) The subjects voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications to local anesthesia; (2) Allergic to or contraindicated with the drugs used in the study (such as opioids, muscle relaxants, etc.) or their ingredients; (3) Patients with craniocerebral injury, cerebrovascular accident history and central nervous system diseases; (4) long-term use of psychotropic drugs, narcotic analgesics, sedative hypnotics or non-steroidal anti-inflammatory drugs patients; (5) Patients who are judged to have difficult airway; (6) Participants who have participated in any clinical trial as a subject within 3 months before enrollment; (7) Other conditions deemed unsuitable for inclusion by the researcher.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-15 (QoR-15) score;

Secondary

MeasureTime frame
Visual analogue scale-Pain score;Incidence of postoperative vomiting;postoperative consumption of opioids;Length of stay;Incidence of postoperative complications;adverse reactions ;Group-time interaction effects on the QoR-15 and its sub-scores were analyzed using a linear mixed model;

Countries

China

Contacts

Public Contacthubailong

Affiliated Hospital of Guizhou Medical University

375896605@qq.com+86 151 8518 4309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026